Diverse neutralizing SARS-CoV-2 antibodies identified from large-scale synthetic phage libraries target rare epitopes and retain binding to variants of concern.

Tue19  Oct11:30am(30 mins)
Room 3A
Dr Tom Yuan


Coronavirus disease 2019 (COVID-19) is an evolving global public health crisis in need of therapeutic options. Passive immunization with monoclonal antibodies (mAbs) represents a promising therapeutic strategy capable of conferring immediate protection from SARS-CoV-2 infection. We describe the discovery and characterization of neutralizing SARS-CoV-2 IgG and VHH antibodies from four large-scale phage libraries, each constructed synthetically utilizing shuffled CDR loops from natural human and llama antibody repertoires. Among these, one neutralizing IgG bound a unique epitope on the N-terminal domain of the SARS-CoV-2 spike protein. Several neutralizing VHH antibodies target a rare epitope that resists mutagenic escape by SARS-CoV-2 variants of concern. We demonstrate that synthetic phage libraries can rapidly yield SARS-CoV-2 S1 antibodies with therapeutically desirable features, including high affinity, unique binding sites, and potent neutralizing activity in vitro, and a capacity to limit disease in vivo.
To view the video assoicated with this lecture click here

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2021